The APRN follow-up at this stage assesses response and determines whether protocol continuation, dose adjustment, or stack modification is appropriate
If your SoloSTAR pen is in cool storage, take it out 1 to 2 hours before you use it to allow it to warm up
activation of PI3K/AKT downstream pathway driving synaptogenesis and anti-apoptotic effects in hippocampus Regulatory status: not approved by the FDA or EMA
Heres the context: serious adverse events are rare and typically associated with pre-existing conditions
Data sources The input parameters for the benefit-harm balance modelling were the relative treatment effects of GLP-1 RAs as compared to placebo, the benefit and harm outcome incidences in untreated individuals, and preference weights (relative importance) of the outcomes.24, 25, 26, 27 A careful selection of valid and applicable evidence relevant to the given decision context is a key step in a benefit-harm analysis.28, 29, 30 The relative treatment effect and baseline risks were obtained from RCTs
